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aBstraCt
Proliferative diabetic retinopathy (PDR) is a major cause of visual impairment in working — age adult population 
worldwide. The purpose of this article is to report the long observation and treatment of a patient with severe PDR. 
We present a case of 42 years old female who had been diagnosed with diabetes mellitus type 1 thirteen years ago, 
presenting a progressive PDR and macular edema in both eyes. The patient was monitored during three years of 
the follow-up. The treatment included laser photocoagulation, anty-VEGF injections and the surgical treatment 
including vitrectomy with ILM peeling and gas or silicone oil tamponade.
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introduCtion
Diabetes mellitus (DM) affected > 350 mil-
lion people worldwide in 2013, and the number 
is estimated to increase to > 590 million people by 
2035 [1]. Over one-third of diabetic patients have 
signs of DR and a third of these are affected with 
vision-threatening diabetic retinopathy (VTDR), 
defined as severe non-proliferative diabetic retinopa-
thy (DR) or proliferative DR (PDR) or the presence 
of diabetic macular edema (DME) [2]. Estimates 
on DR prevalence in type 1 diabetes in Europe and 
the USA range between 36.5–93.6%, with VTDR 
prevalence estimated between 6.7–34.9% [2].
The gold standard treatment for PDR includes 
panretinal photocoagulation (PRP) [3] PRP was 
initiated as a treatment option in the 1960s and 
was documented as beneficial over time. It is 
used to improve the retinal circulation, allow-
ing more oxygen to reach the retina and limit-
ing the formation and release of pro-angiogenic 
cytokines [4]. Adverse effects of PRP as loss of 
peripheral visual field, worsening of traction, 
problems with performing this procedure in eyes 
with media opacity and pain during laser treat-
ment have prompted research into alternative 
therapy for PDR eyes. The elevated intra-ocular 
levels of pro-angiogenic factors, especially vas-
cular endothelial growth factor (VEGF) in the 
pathophysiology of PDR gives the background to 
use anti-VEGF injections to treat and proved to 
be a promising potential alternative.
Intravitreal injections of VEGF inhibitors are 
currently the standard treatment for DME. DME 
affects ~30% of patients with DR and is a major 
factor leading to vision loss [5]. It can occur at any 
stage of DR, and the risk increases with the sever-
ity of the disease: 3% cases with mild non-prolif-
erative diabetic retinopathy (NPDR), 38% cases 
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with moderate-to-severe NPDR, and 71% cases 
with PDR [6].
Surgery for diabetic retinopathy addresses late 
secondary complications. Typical indications for 
vitrectomy are vitreous haemorrhage, tractional reti-
nal detachment, combined tractional–rhegmatog-
enous retinal detachment, and severe fibrovascular 
proliferation (including macular distortion or drag-
ging, tractional macular oedema). These vitreoreti-
nal conditions have been treated with increasingly 
successful outcomes since the introduction of pars 
plana vitrectomy in the early 1970s. [7].
 We report a case of a patient with severe, rap-
idly progressive proliferative diabetic retinopathy in 
both eyes with concomitant macular edema, requir-
ing complex therapy to achieve the best visual out-
comes.
Case report
A forty-two years old female presented in our 
retinal out-patient clinic in February 2015 with 
complains of blurred vision in her left eye from two 
months. Her past medical history revealed 13 years 
lasting insulin dependent diabetes mellitus, she had 
undergone appropriate treatment with levels of 
HbA1c around 8.0%.
At first visit her best-corrected visual acuity was 
on the right eye 1.0 and on the left eye 0.4 with 
Snellen decimal charts. Clinical examination of the 
anterior segment showed early opacifications of the 
lens. Dilated fundus examination revealed the early 
stage of PDR in the right eye (Fig. 1) and advanced PDR changes with clinically significant ME in the 
left eye (Fig. 2). The initial treatment consisted of 
three sessions of PFC because of neovascularization 
due to non-perfused areas of the retina. After this 
time, further laser treatment was impossible because 
of the expanding cataract. The best corrected visual 
acuity was on the right eye 0.5 and on the left eye 
0.1. Cataract surgery (phacoemulsification and in-
traocular lens implantation) was performed on the 
patient’s both eyes. At the first control after cataract 
surgery the best corrected visual acuity in right eye 
improved to 0.7 (Snellen) and on the left eye to 
0.8 (Snellen). But after 2 weeks from surgery, the 
vision of left eye significantly deteriorated and the 
vitreous haemorrhage with tractional retinal detach-
ment involving the macula was diagnosed (Fig. 3). 
Pars plana vitrectomy with removal of fibrovascular 
membranes and ILM peeling and silicone oil tam-
ponade was performed after one month (Fig.  4). 
Five days before the surgery anti-VEGF injection of Figure 1. Neovascularization on the optic nerve disc of the right 
eye
Figure 2. Vitreous haemorrhage due to neovascularisation 
at the optic disc of the left eye
Figure 3. Tractional retinal detachment involving macula due to 
extensive fibrovascular membranes in the left eye
ophthalmologY Journal 2018, Vol. 3, No. 2
70 www.journals.viamedica.pl/ophthalmology_journal
aflibercept was given to the left eye. The PFC was 
continued in both eyes.
Due to PDR and DME in the right eye, the 
patient was given five intravitreal injections of af-
libercept through one year (Fig. 5, 6). After one year 
the second PPV with ILM peeling and removal of 
silicone oil was done in the left eye. Post-surgically 
the corrected visual acuity of the left eye improved 
to 0.3 and has been stable since then there was no 
need to treat the left eye.
Unfortunately, the condition of the right eye 
was getting worse, there was necessary to do anoth-
er PFC session and Yag capsulotomy. The treatment 
was not sufficient, there was vitreous hemorrhage 
and deterioration of vision for hand movement. 
Vitreous surgery with ILM peeling, vitreous haem-
orrhage removal and endolaser and gas tamponade 
was performed (Fig. 7). Five days before the surgery 
anti-VEGF injection of aflibercept was given to the 
right eye. After four months of observation, there is 
no ME and neovascularization in the right eye. The 
corrected visual acuity in the right eye improved 
to 0.4.
disCussion
In the present case report, we have shown the 
complex treatment of progressive DR in a patient 
with type 1 DM. Diabetic retinopathy (DR) is char-
acterized by retinal microvascular damage, based on 
ischaemic changes and increased capillary perme-
ability. The DR it is a complex multifactorial disease 
with many risk factors involved. The most obvious 
systemic risk factor responsible for developing DR 
is hyperglycemia. The result of chronic hypergly-
cemia is activation four main mechanisms that are 
responsible for the occurrence of the DR: increased 
polyol pathway flux, increased advanced glycation 
end-products (AGEs) formation, increased hexos-
amine pathway flux, and activation of protein ki-
nase C (PKC). Improper operation each of this path-
ways leads to early apoptosis, progressive capillary 
occlusion, extracellular matrix overproduction, and 
deposition of plasma proteins. Furthermore, they are 
associated with overproduction of reactive oxygen 
species (ROS). These biochemical changes disturb 
the balance of pro-angiogenesis and antiangiogenesis 
factors involved in the progression of DR. Vascular 
Figure 4. Vitrectomy with removing fibrovascular membanes 
across the posterior pole of the left eye
Figure 6. Macula after anty-VEGF injections and pars plana 
vitrectomy of the right eye
Figure 7. Intraoperative photocoagulation during vitrectomy 
of the right eye
Figure 5. Diabetic macular edema before treatment of the right 
eye
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endothelial growth factor (VEGF), is one of the best- 
known angiogenic factors. The treatment of DMO 
is based on intravitreal anty-VEGF drugs and intra-
vitreal corticosteroids, laser photocoagulation and in 
some cases, the vitreoretinal surgery can be helpful. 
For PDR, the gold standard treatment is laser PFC 
and vitreoretinal surgery, the intravitreal anty-VEGF 
drugs are also used especially in combination with 
PRP or before vitreoretinal surgery.
PFC has stood the test of time and is the only 
evidence-based treatment available for PDR. Stud-
ies have shown almost 50–60% reduction in risk of 
sever visual loss with regression of neovasculariza-
tion post laser treatment [3]. It is postulated that 
PRP decreases the signal for angiogenesis, promotes 
regression of neovascularization, and decreases the 
risk of hemorrhage or development of tractional 
membranes. VEGF levels in the vitreous were 
shown to decline after PRP, and regression of PDR 
was confirmed on the exam [8]. However, PRP has 
well-established limitations. It requires a coopera-
tive patient and a clear view of the retina. Peripheral 
vision is permanently lost with the destruction of 
the peripheral retina, and nyctalopia and a transient 
decline in visual acuity (VA) have also been reported 
[9]. Macular edema can develop or worsen after 
PRP, adversely affecting vision and nearly 4.5% 
show disease progression that ultimately requires 
pars plana vitrectomy (PPV), even when PRP was 
considered “adequate”. This has impelled the efforts 
to provide alternative treatment options that may 
delay or obviate the need for PRP.
In recent years, the development of molecules 
that target VEGF itself has changed the approach 
to diabetic retinopathy. There were a few impor-
tant clinical trials of anti-VEGF for DME. The 
RISE/RIDE studies were two parallel randomized 
control trials that evaluated long-term visual out-
comes in patients with DME who were treated 
solely with ranibizumab. The VIVID/VISTA stud-
ies compared intravitreal aflibercept, 2 mg, every 
4 or 8 weeks with macular laser for DME. Protocol 
T comparison study of bevacizumab, ranibizumab, 
and aflibercept for DME. All of them showed sta-
tistically significant efficacy anti-VEGF in treatment 
DME. During the studies, investigators noted that 
eyes randomized to the anti-VEGF group were more 
likely to have regression of diabetic retinopathy and 
were less likely to develop PDR. DRCR Protocol S 
was a randomized clinical trial designed to deter-
mine whether ranibizumab, 0.5 mg, was similar to 
PRP for PDR. In Protocol S, ranibizumab-treated 
eyes had better VA outcomes, less development of 
DME, and less need for vitrectomy. In eyes with 
PDR and vitreous haemorrhage that makes impos-
sible to do PRP, anti-VEGF treatment can be used 
to treat the underlying retinopathy and may delay 
but not reduce the need for surgery. DRCR Proto-
col H did not show a significant difference in rates 
of vitrectomy at 16 weeks between saline injection 
or ranibizumab-injected eyes. Eyes that received 
ranibizumab did have better VA outcomes. In ad-
dition, anti-VEGF inhibiting angiogenesis may in-
crease the concentration of connective tissue growth 
factor (CTGF) that promotes fibrosis. This, in turn, 
leads to increase vitreoretinal tractions and risk of 
tractional retinal detachment or haemorrhage [10].
Many reports have suggested that vitrectomy 
may be beneficial in the treatment of ME with vit-
reomacular traction [11] but also for diffuse DMO, 
even without any tractional component [12, 13]. 
The vitreous gel contains several growth factors, 
including best known VEGF [8], during vitrectomy 
it is removed from the eye and the presence of them 
could be lower. Furthermore, vitrectomy with sur-
gically induced posterior vitreous detachment may 
not only release any unobserved vitreous traction on 
the macula but may also eliminate the condensed 
fluid containing growth factors.
The Diabetic Retinopathy Vitrectomy Study 
(DRVS) defined the benefit of early vitrectomy in 
the management of severe vitreous haemorrhage. 
The greatest benefit was demonstrated for patients 
with type 1 diabetes who tended to have more 
severe PDR. The benefits of early vitrectomy re-
mained after 4 years follow-up [14].
More recently it has been reported that intravit-
real injection of bevacizumab 1 week preoperatively 
can reduce the risk of bleeding from pathological 
vessels during surgery and in the early post-opera-
tive period [15–16].
Prevention and treatment of diabetic retinopa-
thy are multidirectional, treating a young patient 
with diabetic retinopathy is still a challenge. Long 
life perspective, high expectation, poor long- time 
compliance in young patients makes the treatment 
more difficult. Further analysis of DRCR protocol 
T and S also remind us that despite treatment, 
approximately 30% of eyes with retinopathy will 
continue to worsen.
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